

**LAHVE**  
**&**  
**COCKFIELD**  
 L L P

COUNSELLORS AT LAW  
 28 STATE STREET  
 BOSTON, MASSACHUSETTS 02109-1784  
 TELEPHONE (617) 227-7400  
 FAX (617) 742-4214  
 lc@lahcoc.com

JOHN A. LAHIVE, JR. (1928-1997)  
 THOMAS V. SMURZYNSKI  
 RALPH A. LOREN  
 GIULIO A. DeCONTI, JR.  
 ANN LAMPORT HAMMITTE  
 ELIZABETH A. HANLEY  
 AMY BAKER MANDRAGOURAS  
 ANTHONY A. LAURENTANO  
 KEVIN J. CANNING  
 JOHN V. BIANCO  
 JANE E. REMILLARD  
 FAUSTINO A. LICHAUZO  
 DAVID A. LANE, JR.  
 JEANNE M. DIGIORGIO  
 DEBRA J. MILASINCIC, Ph.D.  
 NICHOLAS P. TRIANO, III

TIM J. DOUROS  
 WILLIAM D. DeVaul  
 SENIOR COUNSEL  
 W. HUGO LIEPMANN  
 JAMES E. COCKFIELD  
 OF COUNSEL  
 JEREMIAH LYNCH  
 WILLIAM A. SCOFIELD, JR.  
 PETER C. LAURO \*  
 JOHN L. WELCH  
 DeANN FORAN SMITH\*\*

\* Admitted in NY only  
 \*\* Admitted in MI only

PATENT AGENTS  
 CATHERINE J. KARA, Ph.D.  
 MEGAN E. WILLIAMS, Ph.D.  
 REZA MOLLAAGHABA, Ph.D.  
 DAVID J. RIKKERS  
 TECHNICAL SPECIALISTS  
 MARIA C. LACOTRIPE, Ph.D.  
 CYNTHIA M. SOROS  
 PETER W. DINI, Ph.D.  
 JENNIFER L. ELLIOTT, Ph.D.  
 LAUREN C. FOSTER, D.Sc.

July 16, 1999

Assistant Commissioner for Patents  
 Washington, D.C. 20231



Re: U. S. Patent Application Serial No. 08/737,904  
 Title: *T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN*  
 Applicant(s): Irwin J. Griffith, et al.  
 Filed: November 20, 1996  
 Examiner: R. Schwadron; Group Art Unit: 1816  
 Attorney Docket No. IMI-040CP3 (075.1 U.S.)

RECEIVED  
 JUL 26 1999

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Preliminary Amendment;
2. Response to "Notice to Comply with Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures";
3. A copy of "Notice to Comply with Requirements for Patent Application Containing Nucleotide and/or Amino Acid Sequence Disclosures";
4. Substitute pages 47-66 containing the Sequence Listing;
5. Diskette containing the Sequence Listing;
6. Transmittal letter for Diskette of Sequence Listing;
7. Request for Three-Month Extension of Time;
8. A check in the amount of \$435.00 (extension fee); and
9. Receipt postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on:

July 16, 1999

Date

Amy E. Mandragouras, Reg. No. 36,207

Respectfully submitted,

LAHVE & COCKFIELD, LLP

Amy E. Mandragouras  
 Reg. No. 36,207

16  
 W/T



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Irwin J. Griffith et al.

Serial No.: 08/737,904


Filed: November 20, 1996

For: T CELL EPITOPES OF RYEGRASS POLLEN  
ALLERGEN

Attorney Docket No.: IMI-040CP3 (075.1 US)

Group Art Unit: 1644

Examiner: R. Schwadron



Assistant Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

7/16/99

Date of Signature and of Mail Deposit

By:

Amy E. Mandragouras  
Reg. No. 36,207  
Attorney for Applicant

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES**


Dear Sir:

Responsive to the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures" and the Examiner's Communication, dated April 9, 1999 (a copy of both of which is attached herewith), Applicants have amended the Sequence Listing submitted on January 6, 1998 to contain the amino acid sequence shown in Figure 16, comply with the new sequence rules and to provide a copy of the sequence listing in computer readable form.

A paper copy of the corrected Sequence Listing and a computer readable form of the sequence listing (diskette), which is identical in substance to the paper copy of the Sequence Listing, in accordance with 37 C.F.R. §1.821(c) and (e), are also submitted herewith.

No new matter has been added to the application. Accordingly it is respectfully requested that the above amendments be entered.

Respectfully submitted,



Amy E. Mandragouras  
Registration No. 36,207  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109

Dated: July 16, 1999



737,90

Application No.: 08/**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.



2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).



3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).



4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."



5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).



6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).



7. Other: See enclosed note

**Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".



An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.



A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).


For questions regarding compliance to these requirements, please contact:-

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Irwin J. Griffith et al.

Serial No.: 08/737,904

Filed: November 20, 1996

For: T CELL EPITOPE OF RYEGRASS POLLEN  
ALLERGEN


Attorney Docket No.: IMI-040CP3 (071.1US)

BOX SEQUENCE

Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

  
Date of Signature and of Mail Deposit

By:


Amy E. Mandragouras  
Reg. No. 36,207  
Attorney for Applicant

**TRANSMITTAL LETTER FOR DISKETTE OF SEQUENCE LISTING**

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, and the Examiner's Communication dated April 9, 1999, we enclose a diskette which contains a computer readable form of the Sequence Listing for the above-identified application.

Substitute pages 47 - 66 are submitted herewith. The material on the enclosed diskette is identical in substance to the enclosed sequence listing. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of §§ 1.821-1.825. No new matter has been added.

  
Respectfully submitted

Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants

Dated: July 16, 1999